{"id":"c91902ec51f3","type":"article","url":"https://hartvaat.nl/2027/01/01/glp-1-remmers-bieden-cardiovasculaire-en-metabole-voordelen-bij-obesitas-en-diab/","title":"GLP-1-remmers bieden cardiovasculaire en metabole voordelen bij obesitas en diabetes type 2","title_en":"GLP-1 based therapy of obesity and type 2 diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Diabetology international","doi":"10.1007/s13340-026-00946-x","source_url":"https://doi.org/10.1007/s13340-026-00946-x","authors":["Jens Juul Holst"],"significance":5,"published":"2026-11-19","source_date":"2027-01-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This narrative review outlines the physiological mechanisms and clinical effects of GLP-1 receptor agonists in patients with obesity and type 2 diabetes. The agents lower HbA1c to below 5.7%, induce substantial weight loss (up to 20%), and demonstrate preventive benefits for cardiovascular, renal, and hepatic complications. Clinically, the authors emphasize gradual dose titration, concurrent lifestyle modifications, and a structured discontinuation plan to mitigate adverse effects and rebound symptoms.","created":"2026-11-13T01:48:34Z","updated":"2026-11-13T01:48:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze narratieve review beschrijft het fysiologische mechanisme en de klinische effecten van GLP-1-receptoragonisten bij patiënten met obesitas en diabetes type 2. De middelen verlagen het HbA1c tot onder de 5,7%, leiden tot significante gewichtsafname (tot 20%) en tonen preventieve effecten op cardiovasculaire, renale en hepatische complicaties. Voor de klinische praktijk benadrukken auteurs een gefaseerde dosering, levensstijlaanpassingen en een duidelijk plan voor het afbouwen van de therapie om bijwerkingen en rebound-effecten te voorkomen.","abstract_original":"GLP-1 is 30-amino acid peptide that is secreted from the intestine in response to food intake. The release mechanism involves luminal exposure to as well as absorption and metabolism of the major nutrients. It functions mainly as a part of the ileal brake mechanism whereby nutrient entry in distal segments of the small intestine inhibit gastrointestinal secretion and motility as well as appetite and food intake, signalling nutritional abundance. It also functions as a second line incretin hormone. It acts on the brain via sensory vagal afferents, but also interacts with exposed neurons expressing the GLP-1 receptor in the circumventricular organs, in turn activating brain nuclei involved in appetite regulation and reward. High doses of GLP-1 cause nausea and vomiting, but slow dosing titration mitigates this. GLP-1 Receptor Agonists owe their actions to these physiological mechanisms and therefore represent powerful antidiabetic agents (A1c levels below 5.7%) and cause major weight loss (up to 20%), but also appear to reduce the systemic low-grade inflammation of obesity and type 2 diabetes and to exert beneficial action on the blood vessels, providing the GLP-1RAs with preventive effects on cardiovascular, hepatic, renal and central nervous system complications. Orally active GLP-1rAs have also been developed. It is emphasized that GLP-1RA therapy should be accompanied by lifestyle changes for efficacy and to prevent side effects of the weight loss. In addition, any prescription of a GLP-1RA should include a plan to mitigate adverse effects of treatment termination. Nevertheless, GLP-1RAs represent a major breakthrough in the therapy of metabolic disease and are now included among the essential medicines of the WHO."}